Abstract: A method includes the step of receiving electrocardiogram (ECG) data associated with a plurality of patients and an electrocardiogram configuration including a plurality of leads and a time interval. The electrocardiogram data includes, for each lead included in the plurality of leads, voltage data associated with at least a portion of the time interval. The method also includes training an artificial intelligence model on the ECG data, tuning the artificial intelligence model using data from a device having fewer leads than the plurality of leads, and evaluating the artificial intelligence model on additional data received from the ECG data.

Abstract: The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABAB agonist, lesogaberan (AZD3355), or related compounds.

Abstract: Presented herein are methods and systems of collecting and preserving a biological sample. The methods and systems include the use of a dissolvable collection film to collect the samples and dissolving the film in to a buffer or stabilizing solution contained in a sealable container.

Abstract: Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.

Abstract: Provided herein are methods and compositions for treating gastrointestinal disorders using beta blockers. Compositions comprising Beta blockers such as Timolol and Nadolol are used to treat diseases including ulcerative colitis, IBD and Crohn's disease. The Compositions are administered orally or rectally, at doses that provide a peak plasma concentration of less than 10 ng/ml.

Abstract: Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.